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MRP2 encoded by ABCC2 gene is involved in the secretion of numerous drugs and endogenous substrates. Patients with Dubin-
Johnson syndrome due to mutation in ABCC2 gene have elevated urinary coproporphyrin ratio (UCP I/(I + III)). Here we
investigated whether this ratio could serve as a biomarker of MRP2 function. Phenotype-genotype relationships were studied
in 74 healthy subjects by measuring individual UCP I/(I + III) ratio obtained on 24-hour urine and by analyzing ﬁve common
SNPs in ABCC2 gene. The UCP I/(I + III) ratio varied from 14.7% to 46.0% in our population. Subjects with 3972TT genotype
had a higher ratio (P = .04) than those carrying the C allele. This higher UCP I/(I + III) ratio was correlated with a higher level of
isomer I excretion. This study provides a proof of concept that UCP I/(I + III) ratio can be used as a biomarker of MRP2 function
in clinical studies as it provides quantitative information about the in vivo activity of MRP2 in a given patient.
1.Introduction
Excessive accumulation of drugs and consequent drug-
induced toxicity may arise from a defect in the ability to
secrete drugs into the bile or urine. Various membrane
transporters, including those of the ATP-binding cassette
(ABC) family, are involved in these processes in the kidneys
and liver. One such transporter, multidrug resistance protein
2 (MRP2), encoded by the ABCC2 (ABC subfamily C2)
gene, plays a key role in the secretion of numerous drugs
and drug metabolites [1]. Studies in Mrp2-deﬁcient rodents
have conﬁrmed the relevance of this transporter in drug
pharmacokinetics, with exposure levels reaching 140% to
615% of those in normal animals, depending on the drug
considered [2–5].
MRP2 is also involved in the elimination of various
endogenous compounds. Uroporphyrins and copropor-
phyrins, natural intermediates of heme biosynthesis, are the
main porphyrins in excess in the plasma. Coproporphyrins
exist in two isomeric forms (isomer I and isomer III), both
physiologicallyexcretedbytheliverandthekidney.Although
no direct lines of in vitro evidence indicated a role for
MRP2 in coproporphyrins transport, animal studies recently
conﬁrmed the major role of Mrp2 in the elimination of these2 Journal of Biomedicine and Biotechnology
compounds from the plasma [6]. The authors used a bile
ﬁstula rat model to study the biliary and urinary excretion
of coproporphyrin isomers in wild-type and Mrp2-deﬁcient
rats receiving a continuous infusion of equimolar amounts
of the coproporphyrin isomers. Mrp2-deﬁcient rats excreted
larger amounts of coproporphyrins in urine, with very low
levels in bile compared to wild-type rats. The proportion of
each isomer in urine also diﬀered between the two groups
of animals. Isomer III predominated in the urine of wild-
type animals, whereas the proportion of isomer I was higher
in the urine of Mrp2-deﬁcient rats, accounting for 70% of
the coproporphyrins present. These results conﬁrmed that
MRP2 is involved in the excretion of coproporphyrins and
that the impairment of MRP2 activity leads to a switch in
excretionpattern,fromexcretioninbiletoexcretioninurine.
Dubin-Johnson syndrome (DJS) is an autosomal reces-
sive disorder in which the production or function of MRP2
protein is impaired [7, 8]. Missense, nonsense, or splice-
site mutations in the ABCC2 gene are responsible for this
syndrome. It is characterized by conjugated hyperbiliru-
binemia and a deposition of a melanin-like pigment in
hepatocytes, with liver function otherwise normal. DJS
patients also present a modiﬁed pattern of coproporphyrin
isomers excretion in urine, characterized by a high urinary
coproporphyrin I-to-coproporphyrin I + III ratio (UCP I/(I
+ III) ratio) [9, 10]. Subjects carrying a homozygous muta-
tion in the ABCC2 gene have a UCP I/(I + III) ratio greater
than 80%, whereas in normal subjects it is only about 30%.
Subjects with heterozygous mutations have moderately high
UCP I/(I + III) ratios (about 60%) [9]. Based on results from
studiesonthedistributionoftransportersinliverandkidney
[11] and results of Moriondo et al. [6], Frank et al. [9], and
Kaplowitz et al. [12], we propose a possible physiopathologic
pathway for coproporphyrin elimination (Figure 1).
Apartfrommutations,severalcommonsinglenucleotide
polymorphisms (SNPs) in the ABCC2 gene have also been
identiﬁed [13, 14]. The phenotypic consequences of these
SNPs have been evaluated indirectly, by studying the
pharmacokinetics of several MRP2 substrates. These studies
showed an impact of particular SNPs (−24C/T, 1249G/A,
3563T/A, 3972C/T, and 4544G/A) on methotrexate [15],
mycophenolic acid [16], irinotecan [17], pravastatin [18],
and doxorubicin [19] elimination. Identifying patients with
low levels of MRP2 activity before the administration of a
drug that might act as a substrate for MRP2 could therefore
potentially lower the risk of overexposure. However, no
phenotypic marker of MRP2 activity has yet been identiﬁed.
We hypothesized that the pattern of coproporphyrin
elimination in urine would constitute a potential biomarker
for MRP2 activity. We thus analyzed phenotype-genotype
relationships, by studying the excretion of coproporphyrin
isomers in urine and by genotyping several ABCC2 SNPs in
a group of healthy volunteers.
2. Methods
2.1. Subjects and Study Procedures. Eighty healthy human
volunteers were recruited for the COVOL study (Clini-
caltrial.gov number NCT00746044). Caucasian male and
female subjects were eligible for participation, provided they
met the following criteria: at least 18 years of age, no clinical
abnormality (investigator’s clinical judgment), no porphyria
(according to the urine analysis results), and normal renal
and liver functions. Subjects had no chronic treatment
other than oral contraception in female subjects (comprising
ethynylestradiol, 20 to 30μg) and took no medication in the
two weeks preceding the study. The COVOL protocol was
approved by the ethics committee of Tours University Hos-
pital, France. All subjects gave written informed consent for
genetic testing and urine analysis. A blood sample was drawn
from each subject for SNP analysis. For coproporphyrin
determinations, urinary samples were obtained according
to the following timetable: day 1, 5mL of the morning
micturition sample was dispensed into aliquots, and all
subsequent urine over the next 24 hours was collected. We
also collected 24-hour urine samples on two other occasions,
within a maximum of two months. Sodium carbonate was
immediately added to samples as an oxidizing agent, and
samples were then kept frozen until analysis. Procedures for
urine handling and storage were established before this study
[20]. Urine volumes were precisely measured.
2.2. HPLC Analysis of Coproporphyrins and UCP I/(I + III)
Ratio Determination. Urinary coproporphyrin levels were
determined by HPLC (high-performance liquid chromatog-
raphy), using a method described in more detail elsewhere
[20]. Brieﬂy, analyses were carried out with a chromato-
graphic system composed of a pump and an Ultimate
3000 autosampler (Dionex, Sunnyvale, Calif, USA). The 474
ﬂuorescence detector (Waters, Saint-Quentin-en-Yvelines,
France) was set at 365nm for excitation and 624nm for
emission. Chromatographic separation was achieved on a
reverse-phase C18 Symmetry (Waters, Saint-Quentin-en-
Yvelines, France) column (4.8 × 250mm) with a precolumn.
All chemicals were HPLC grade. The mobile phase was a
gradient of acetonitrile (Carlo-Erba, Val de Reuil, France)
and 0.015M sodium acetate (Merck, Darmstadt, Germany)
buﬀer, adjusted to pH 4 with glacial acetic acid (Carlo-Erba,
Val de Reuil, France).
Urine samples (400μL) were acidiﬁed by adding 20μL
10N hydrochloric acid (Carlo-Erba, Val de Reuil, France),
vortexing for 20 seconds and centrifuging the mixture for
10 minutes at 18000 × g. We then injected 50μL of the
supernatant into the chromatography system. The limits of
quantiﬁcation were 7nmol/L for isomer I and 10nmol/L for
isomer III. The UCP I/(I + III) ratio was determined with a
precision of about 99%.
We quantiﬁed both coproporphyrin isomers in urine
from standard curves obtained with commercially available
calibrators (Recipe, Munich, Germany). The UCP I/(I + III)
ratio was obtained by dividing the peak height of isomer I by
the sum of peak heights of isomers I and III.
2.3. DNA Analysis. Genomic DNA was extracted from
peripheral blood leukocytes according to the kit manu-
facturer’s protocol (FlexiGene DNA kit, QIAGEN, Hilden,
Germany). Five SNPs within the ABCC2 gene were selected
for genotyping on the basis of previous studies evaluatingJournal of Biomedicine and Biotechnology 3
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Figure 1: Proposed physiopathologic pathway for coproporphyrin elimination. This model was established on the basis of experimental
data for both structure-aﬃnity relationships for the interaction between coproporphyrin isomers and MRP2 [12] and of the measurement
of coproporphyrin excretion in the bile and urine of Mrp2−/− or wild-type rats [6]. Calculations were based on an equimolar perfusion
of coproporphyrin isomers in blood (for illustration, 10 molecules of each isomer are considered) and on the higher aﬃnity of MRP2
for isomer I than for isomer III. The white squares represent molecules of isomer I and the black squares molecules of isomer III. Each
part of the ﬁgure illustrates a particular situation: physiologic conditions (a); no MRP2 activity (b). R represents the UCP I/(I + III) ratio,
calculated as the number of molecules of isomer I over the total number of molecules of isomer I and isomer III. In physiologic conditions
(a), coproporphyrins enter the hepatocyte via an inﬂux transporter, which may be OAT2, OATP1B1, OATP1B3, or another transporter.
Coproporphyrins are then excreted predominantly in bile, via MRP2. As MRP2 has a higher aﬃnity for isomer I than for isomer III due
to a conformational advantage [12], the biliary coproporphyrin ratio is thus ∼70% (67% in our theoretical example). A minor fraction
may be secreted via BCRP and/or other transporters located in the canalicular membrane of hepatocytes. The fraction not excreted in bile
returns to the blood via eﬄux transporters (possibly MRP3/ABCC3, which has a substrate speciﬁcity similar to or overlapping that of MRP2,
MRP1/ABCC1, or MRP4/ABCC4, all located in the sinusoidal membrane; for review, see Borst et al. [26]). The remaining coproporphyrins
(three times as much isomer III as isomer I) are excreted then in the urine via MRP2. The resulting UCP I/(I + III) ratio in normal subjects
is thus ∼30% (25% in our theoretical example). If MRP2 is entirely absent (b), as in DJS, only very small amounts of coproporphyrins are
excreted in bile, probably via BCRP or other transporters. Most of the coproporphyrins are returned to the blood, presumably via MRP3,
which is upregulated in Mrp2−/− mice [6, 27], or by MRP4. The kidney thus received both isomers, in equimolar proportions. Elimination
in urine involves transporters other than MRP2 (possibly MRP4 or BCRP), with the same stereospeciﬁcity as MRP2 for the two isomers.
According to this model, the urinary ratio should be about 80% (75% in our example), consistent with values observed in DJS patients.
their impact on MPR2 activity [13, 19, 21–23]. The
ﬁve SNPs (−24C/T (rs717620), 1249G/A (rs2273697),
3563T/A (rs17216324), 3972C/T (rs3740066), and 4544G/A
(rs8187710)) were genotyped by direct sequencing. PCR
was carried out in a total volume of 50μL containing
1 0 0 n go ft o t a lD N A ,1 0 p m o lo fe a c hp r i m e r( Table 1)
[24], 0.2mmol/L dNTPs, 1.5mmol/L MgCl2, and 1.5 units
of Taq polymerase (Invitrogen, Carlsbad, Calif, USA). The
ampliﬁcation protocol was as follows: initial denaturation at
94◦Cf o r5m i n u t e s ,3 5c y c l e s( 1m i n u t ea t9 4 ◦C, 30s at 60◦C
(rs17216324, rs2273697, and rs8187710), 56◦C (rs717620),
or 65◦C (rs3740066), and 1 minute at 72◦C), and a ﬁnal
extension at 72◦C for 10 minutes. Then, PCR products were
puriﬁed with a DNA gel extraction kit (Millipore, Billerica,
Mass, USA) and sequenced with the Big Dye Terminator
(version 3.1) cycle sequencing kit (Applied Biosystems,
Carlsbad, Calif, USA). Sequencing analysis was carried out
on an Applied 3130XL automated DNA capillary sequencer
(Applied Biosystems, Carlsbad, Calif, USA).
2.4. Statistical Analysis. The normality of the UCP I/(I +
III) ratios’s distribution was tested using the Shapiro-Wilk
test. A Mann-Whitney test was performed to compare UCP
I/(I + III) ratio between men and women. UCP I/(I + III)
ratios were grouped into 4 categories based on distribution
according to quartiles. The lower quartile (Q1) included the
data of the 25% of patients with the lowest ratio; quartiles
Q2 and Q3 extended 25% below and above the median ratio,4 Journal of Biomedicine and Biotechnology
Table 1: Primers used for genotyping ABCC2 (MRP2) polymorphisms.
SNP Reference Primer sequence (5  →3 )F r a g m e n t s i z e , b p
ABCC2 5 UTR rs717620 F CCTTTACGGAGAACATCAGA 252
−24C/T R TTCTGGTTCTTGTTGGTGAC
ABCC2 exon 10 rs2273697 F GTGCCTTGGAGAAGCTGTGT 478
1249G/A R TTGCCCAAACTCCCATTAAG
ABCC2 exon 25 rs17216324 F GTAAGCTGTGCCCATCAAGG 383
3563T/A R CCTCCCACCGCTAATATCAA
ABCC2 exon 28 rs3740066 F GAGTCCTGGGTGGACTGTTC 291
3972C/T R CCAGCTGCTCTCCACTCTGT
ABCC2 exon 32 rs8187710 F AAATGCCTAGACTTGAGATGCTG 449
4544G/A R CGTGAAATTCAGGACAGTGG
respectively; the upper quartile (Q4) included the 25% of
patients with the highest ratio. Student’s t test was used to
compare the concentrations of the two isomers in patients
with the highest ratio (Q4) versus others.
We used a Bland and Altman plot and its intraclass
correlation coeﬃcient (ICC) to compare the UCP I/(I +
III) ratios obtained for the morning sample and the 24-
hour urine samples. The same test was used to evaluate the
stability of the UCP I/(I + III) ratio (obtained for the ﬁrst,
second, and third 24-hour urine samples) over time in a
given subject (intraindividual variability on three separate
occasions).
All SNPs were tested for Hardy-Weinberg equilibrium.
A search for a relationship between UCP I/(I + III) ratio
(obtained for the ﬁrst 24-hour urine samples) and each
SNP was ﬁrst performed using a Kruskal-Wallis rank sum
test and the post hoc Siegel-Castellan test. Then, a Mann-
Whitney test was used to compare UCP I/(I + III) ratio as
af u n c t i o no fe a c hABCC2 polymorphism (wild-type allele
carriers versus homozygous variant for each SNP). Statistical
analysis was performed with R version 2.8.0, an open source
program developed by the R Foundation for Statistical Com-
puting (Vienna, Austria). We used THESIAS software (Paris,
France) [25]t oc o n s t r u c tABCC2 haplotypes and to analyze
associations between haplotypes and UCP I/(I + III) ratio.
3. Results
3.1. Distribution of UCP I/(I + III) Ratio in Healthy
Volunteers. Eighty subjects were recruited (38 men and 42
women). Mean age was 25.2 (±6.5) years, mean weight was
63.1 (±9.9)kg, and mean height was 169.0 (±15.4)cm. Five
subjects were excluded from the analysis because we were
unable to obtain the totality of samples (urine or DNA)
and one was excluded because he took a nonsteroidal anti-
inﬂammatory drug (NSAID) during the study.
UCP I/(I + III) ratio varied from 14.7% to 46.0% in our
group (as determined from the ﬁrst 24-hour urine sample)
with a median at 28.0% (Q1: 25.1%; Q4: 33.6%; Figure 2).
The distribution of UCP I/(I + III) in our population was
not Gaussian (P = .21). No diﬀerence in UCP I/(I + III)
ratio was found between men (median (interquartile range))
(30.0 (7.8)%) and women (28.3 (9.1)%; P = .24). In parallel,
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Figure 2: Distribution of UCP I/(I + III) ratio in our population.
we did not observe any correlation (r2 = 0.003, P = .66)
between the UCP I/(I + III) ratio and the age of the subjects.
Subjects with a high UCP I/(I + III) ratio (greater than
33.6%) had higher isomer I concentrations in urine (mean ±
sd; 25.6 ± 12.0nmol/L) than did the other subjects (16.5 ±
8.6nmol/L) (P = .007), whereas no diﬀerence in the concen-
tration of isomer III was observed between these two groups
(41.3 ± 24.5nmol/L and 48.5 ±29.7nmol/L, resp.; P = .35).
3.2. Stability of UCP I/(I + III) Ratio over Time in Healthy
Volunteers. Good concordance (ICC = 0.67 with a conﬁ-
dence interval of [0.42; 0.96]) between the UCP I/(I + III)
ratios measured for the morning urine sample and those
obtained for the 24-hour urine samples was observed in our
population (Figure 3). The exclusion of the one subject with
discordant UCP I/(I + III) ratios (black circle) increased the
ICC to 0.90, with a conﬁdence interval of [0.77; 0.97]. It is
therefore possible to use morning urine samples in place of
24-h urine samples.
Comparisons of the UCP I/(I + III) ratios obtained for
the same subject on three separate occasions (24-h urine
samples) showed that the UCP I/(I + III) ratio was stableJournal of Biomedicine and Biotechnology 5
Table 2: Relationships between UCP I/(I + III) ratio and each ABCC2 polymorphism using the Mann-Whitney test.
Polymorphism Genotype Frequency no. (%)
Median [interquartile
range] UCP I/(I + III)
ratio (%)
P value∗
ABCC2 −24 C/T
CC 46 (62.2)
26.9 [8.4] .08 CT 25 (33.8)
TT 3 (4.0) 33.8 [5.8]
ABCC2 1249 G/A
GG 52 (70.2)
27.8 [8.4] .39 GA 21 (28.4)
AA 1 (1.4) 33.6 [na]
ABCC2 3563 T/A
TT 64 (86.5)
28 [8.6] — TA 10 (13.5)
AA 0 —
ABCC2 3972 C/T
CC 29 (37.7)
26.7 [7.6] .04 CT 37 (49.3)
TT 8 (12.0) 33.1 [3.1]
ABCC2 4544 G/A
GG 64 (86.5)
28 [8.6] — GA 10 (13.5)
AA 0 —
∗Wild-type allele carriers versus homozygous variant.
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Figure 3: Mean UCP I/(I + III) ratio determined for morning and
24-hour urine samples (Bland and Altman plot). The black circle
represents the subject with highly discordant UCP I/(I + III) ratio
values between morning and 24-hour urine samples.
over time, with a median coeﬃcient of variation (CV) of
7.8%, except in three subjects for whom CV values of 21 to
27% were obtained. The ICC values of these subjects were in
the normal range, at 0.80 [0.64; 0.87]. Thus, UCP I/(I + III)
ratio remains stable over time in a given subject.
3.3. Genotype-Phenotype Correlation in Healthy Subjects.
The results of the genotypic analysis for the 74 volunteers
are summarized in Table 2. The “minor” allele frequencies
(MAFs) of the −24C/T, 1249G/A, 3563T/A, 3972C/T, and
4544G/A polymorphisms of ABCC2 were 0.22, 0.15, 0.08,
0.34, and 0.08. All polymorphisms were in Hardy-Weinberg
equilibrium. We found a linkage disequilibrium between
−24C/T and 3972C/T (r2 = 0.47, D  = 1) and complete
linkage disequilibrium between 3563T/A, and 4544G/A
(r2 = 1, D  = 1). Haplotype analysis was then performed for
four SNPs (−24C/T, 1249G/A, 3563T/A, and 3972C/T). Five
haplotypes were observed: CGTC (f [frequency] = 0.42),
CGTT (f = 0.15), CGAC (f = 0.07), CATC (f = 0.16),
and TGTT (f = 0.21).
In a preliminary trend analysis, we observed a nonsignif-
icantdiﬀerenceinUCPI/(I+III)ratioaccordingto3972C/T
genotype (P = .08). The same was true for the −24C/T
SNP (P = .17). When we grouped together CC and CT
subjects, we found that subjects who were homozygous TT
for the 3972C/T SNP had higher UCP I/(I + III) ratios (P =
.04) than allele C carriers (Figure 4(a)) .T h es a m ew a st r u e
(P = .08) for −24TT subjects (Figure 4(b)). We found no
relationshipwithanyoftheotherthreeABCC2SNPsstudied.
Similarly, no association was found between haplotypes and
UCP I/(I + III) ratio.
4. Discussion
This is the ﬁrst study exploring the role of MRP2 poly-
morphisms in coproporphyrin elimination in humans, with
the ultimate aim of evaluating UCP I/(I + III) ratio as a
biomarker of MRP2 function in vivo.
Measurements of the UCP I/(I + III) ratio in 74
healthy subjects eﬀectively demonstrated wide interindi-
vidual variability, with a median (range) of 28.0 (14.7–
46.0)%, consistent with values previously reported for the
general population [9]. By contrast, UCP I/(I + III) ratio
remained stable over three diﬀerent measurements made in6 Journal of Biomedicine and Biotechnology
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Figure 4: Relationship between UCP I/(I + III) ratio and ABCC2 genotypes [(a) 3972C/T and (b) −24C/T]. Boxes represent the 25th and
75th percentiles. The median is indicated by a line, and the 10th and 90th percentiles are indicated by whiskers.
individual subjects taking no drug that might interfere with
MRP2 at any time during the study period, indicating that
this ratio is indeed an individual characteristic. Note that
some female subjects took an oral contraception (n = 20)
comprising ethinylestradiol (EE), known to decrease bile
ﬂow and to decrease expression and activity of Mrp2 in
rats when administered subcutaneously at 5mg/kg/day [28].
Consistent with the very low EE dosage used, we found no
diﬀerence in UCP I/(I + III) ratio between women who took
EE and those who did not (Mann-Whitney test, P = .61).
Genotype analysis was conducted with the ﬁve SNPs
of the ABCC2 gene previously shown to be involved in
the pharmacokinetics or toxicity of MRP2 substrates. This
genetic strategy was speciﬁcally selected to study the phe-
notypic consequences of these frequent common SNPs, and
not of rare mutations leading to DJS (incidence = 0.05%).
The minor allele frequencies (MAFs) for the ABCC2 SNPs
in our subjects were consistent with those reported in the
HAPMAP project on a Caucasian population (residents
of Utah descended from immigrants from northern and
western Europe) [29] and none of these SNPs deviated
from Hardy-Weinberg equilibrium. As 4544G/A was in total
linkage disequilibrium with 3563T/A (r2 = 1, D  = 1), it was
not included in the haplotype analysis.
Our phenotype-genotype analysis revealed that homozy-
gous 3972T and −24T subjects had higher UCP I/(I + III)
ratios than wild-type allele carriers. We found no statistical
relationship with the other polymorphisms of ABCC2.
These results are concordant with experimental results.
The 3972C/T polymorphism leads to a decreased MRP2
protein expression associated with an impaired transport
activity [30]. As the 3972C/T polymorphism is synonymous,
its inﬂuence on MRP2 activity is probably mediated by the
variation of another SNP in very strong linkage disequi-
librium [16]. We eﬀectively found a linkage disequilibrium
between this SNP and the −24C/T polymorphism, although
not complete (r2 = 0.47, D  = 1), explaining why the
trendforanassociationbetween −24C/Tpolymorphismand
UCP I/(I + III) was not signiﬁcant contrary to 3972C/T.
Another hypothesis is that 3972C/T SNP may aﬀect pro-
tein conformation and substrate speciﬁcity [31], modulate
protein production by altering mRNA secondary structure
and stability [32, 33], or lower translation eﬃcacy [30].
The −24C/T polymorphism is located in the 5 -UTR, a
region that appears essential for ABCC2 transcription in
liver cells [34]. Similarly, the −24T allele was associated
with reduced ABCC2 mRNA levels, [21]a n dr e d u c e dM R P 2
protein expression albeit without signiﬁcant diﬀerence in
transport activity [30]. This SNP could aﬀect ABCC2 mRNA
stability and/or translational activity [30].
Laechelt et al. [30] showed in cells transfected with
−24T or 3972T ABCC2 cDNA that 3 haplotypes, H9
(−24C/1249G/3972T), H10 (−24T/1249G/3972C), and H12
(−24T/1249G/3972T), were associated with altered MRP2
protein expression (33%, 73%, and 44%, resp., as compared
to wild-type haplotypes) and altered eﬄux rates (signiﬁcant
for 3972T-containing haplotypes H9 and H12). This con-
ﬁrms that both polymorphisms inﬂuence the function of
ABCC2 transporter, the eﬀect of 3972C/T being predomi-
nant. We did not ﬁnd any relationship between haplotypes
in our population and the UCP I/(I + III) ratio. Our results
show a SNP-dependent coproporphyrin elimination and
conﬁrmatory studies in a larger population are required to
analyze haplotypes and to increase the study power.
Severalauthorsalsoassessedthefunctionalconsequences
of ABCC2 SNPs for the pharmacokinetics of drugs acting
as substrates of MRP2. In their study on pediatric cancer
patients, Rau et al. showed that children carrying the
−24T allele had lower levels of MTX clearance than other
children, this diﬀerence being most marked (tripling of
the area under the curve AUC) in female patients [15].
Naesens et al. showed an increase of the mycophenolic acidJournal of Biomedicine and Biotechnology 7
AUC (17% at day 42 after transplantation, P = .008) in
renal allograft recipients carriers of the −24T allele and a
similar relationship in patients carriers of the 3972T allele
[16]. Recently, Laechelt et al. found that subjects bearing
the 3972T allele with or without the −24T presented an
increased AUCoral of talinolol. This indicates that screening
for ABCC2 polymorphisms may help to better understand
the interindividual diﬀerences in the pharmacokinetics of
some drugs.
Beyond the genetic factors, the activity of MRP2 trans-
porter can also be modulated by exogenous factors, and
particularly drug interactions, by phenotypical modiﬁcation
of its activity [1]. Personal data, not yet published, show that
the basal value of UCP I/(I + III) ratio in a given subject does
indeed increase following the administration of an MRP2
inhibitor, suggesting that UCP I/(I + III) ratio reﬂects MRP2
activity at a given time in a given patient. In subjects of
the present study taking no drug, comparable UCP I/(I +
III) ratios were obtained for morning micturition and 24-
hour urine. So, based on a simple urine sample, UCP I/(I +
III) ratio is a practicable test for future prospective studies
evaluating its predictive value for the pharmacokinetics of
MRP2 substrates.
The precise mechanism controlling the secretion of
coproporphyrin isomers into urine has yet to be fully
described.EvidencefortheinvolvementofMRP2inthispro-
cess is provided by the higher UCP I/(I + III) ratio observed
in DJS patients and Mrp2-deﬁcient rats and is supported by
the results of our study showing that a moderate impairment
ofMRP2functionduetopolymorphismsincreasesthisratio,
althoughtoalesserextentthaninsubjectscompletelylacking
the protein. Frank et al. suggested that the higher UCP I/(I
+ III) ratio in DJS patients resulted from the excretion of
larger amounts of isomer I in urine [9], but these authors
did not quantify each product separately. We showed, with
24-hour urine samples, that a high UCP I/(I + III) ratio
(subjects from Q4) eﬀectively resulted from an increase in
isomer I excretion in urine. We are currently conducting
transport studies on MDCKII (Madin Darby Canine Kidney
II) cells to verify if one or both coproporphyrin isomers are
substrates of MRP2. Increased excretion of isomer I in urine,
associated with an inverted proportion of the two isomers
in case of MRP2 defect (increase of the UCP I/(I + III)
ratio),suggeststhatcoproporphyrineliminationmayinvolve
at least a second transporter in the kidney. The proposed
physiopathologic pathway in Figure 2, accounting for the
inverted proportions of isomers in Dubin-Johnson patients
(ratio ∼80%) compared to healthy subjects (ratio ∼30%), is
consistent with the intermediate ratio (about 40%) observed
in subjects with lower MRP2 activity, such as subjects with
24TT or 3972TT genotypes. In this case, only part of the
coproporphyrins are excreted into the bile via MRP2, again
with a higher proportion of isomer I (biliary ratio ∼70%)
than isomer III, due to the higher aﬃnity of MRP2 for
isomer I. The remaining coproporphyrins are excreted in
urineviaMRP2orothertransporters(suchasBCRP,MRP4).
KnowingthatthereislessofisomerIthanofisomerIIIwhich
arrivesatthekidney,nocompetitionoccursandtheUCPI/(I
+ III) ratio is about 35 to 45%.
In turn, UCP I/(I + III) ratio provides quantitative
information about the in vivo activity of MRP2. This would
account for the variation of UCP I/(I + III) ratio with
ABCC2genotype,beinghighinpatientswithDJSmutations,
moderately high in subjects with relevant polymorphisms,
and normal in wild-type subjects.
In our opinion, this study provides a proof of concept
that UCP I/(I + III) ratio can be used as a biomarker of
MRP2 function in clinical studies. Indeed, it is stable over
time in a given subject, provided that no environmental
factor (e.g., drug interaction) modiﬁes MRP2 function. It
depends on genetic characteristics, and the administration
of an MRP2 inhibitor increases the ratio (personal data).
Thus, UCP I/(I + III) ratio may reﬂect the functionality of
MRP2 in a given patient, at a given time, taking into account
individual genotype and concurrent environmental factors.
Wenowneedtocarryoutaprospectivestudytodemonstrate
that the UCP I/(I + III) ratio measured at the time of drug
intake is eﬀectively correlated with the pharmacokinetics of
the drug. We are currently carrying out such a study with
methotrexate, a well-known substrate of MRP2.
5. Conclusion
MRP2 is involved in the elimination of several drugs. No
biomarker of its activity is available so far. Previous studies
have shown that the urinary coproporphyrin ratio UCP I/(I
+ III) is elevated in patients with Dubin-Johnson syndrome,
as a consequenceof mutations in the ABCC2gene. In healthy
volunteers, the ratio was highly variable between subjects
a n dt e n d e dt ob ee l e v a t e di ns u b j e c t sh o m o z y g o u sf o rt w o
distinct SNPs, 3972C/T and −24C/T. This study provides a
proof of concept that UCP I/(I + III) ratio can be used as a
biomarker of MRP2 function in clinical studies as it provides
quantitative information about the in vivo activity of MRP2
in a given patient. Based on these results, we propose the use
of UCP I/(I + III) ratio to evaluate MRP2 activity in future
pharmacokinetic studies.
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